Literature DB >> 32917950

Silencing of long non-coding RNA FOXD2-AS1 inhibits the progression of gallbladder cancer by mediating methylation of MLH1.

Jun Gao1, Chao Dai1, Xin Yu1, Xiang-Bao Yin1, Wen-Jun Liao1, Yong Huang1, Fan Zhou2.   

Abstract

Evidence has documented the tumor-promoting properties of long non-coding RNA (lncRNA) FOXD2 adjacent opposite strand RNA 1 (FOXD2-AS1) in many cancers. However, little is known about its role in gallbladder cancer. Here, we aimed to characterize the functional relevance of lncRNA FOXD2-AS1 in gallbladder cancer and the possible mechanisms associated with methylation of MutL homolog-1 (MLH1). Initially, microarray-based gene expression profiling of gallbladder cancer was employed to identify differentially expressed lncRNAs. Next, the expression of lncRNA FOXD2-AS1 was examined, and the cell line presenting with the highest lncRNA FOXD2-AS1 expression was selected for subsequent experimentation. Then, the interaction between lncRNA FOXD2-AS1 and MLH1 was identified. The effect of lncRNA FOXD2-AS1 on proliferation, migration, invasion, and apoptosis as well as tumorigenicity of transfected GBC-SD cells was examined with gain- and loss-of-function experiments. We found that lncRNA FOXD2-AS1 was highly expressed, while MLH1 was poorly expressed in gallbladder cancer cells. Besides, lncRNA FOXD2-AS1 could promote MLH1 methylation by recruiting DNMT1 to the MLH1 promoter, and consequently inhibit MLH1 transcription. Silencing of lncRNA FOXD2-AS1 or overexpression of MLH1 inhibited gallbladder cancer cell proliferation, invasion, and migration, while facilitating cell apoptosis in vitro as well as retarding tumor growth in vivo. Thus, silencing of lncRNA FOXD2-AS1 suppressed the progression of gallbladder cancer via upregulation of MLH1 by inhibiting MLH1 promoter methylation. These findings present lncRNA FOXD2-AS1 knockdown as a potential candidate for the treatment of gallbladder cancer.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32917950     DOI: 10.1038/s41434-020-00187-w

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  5 in total

Review 1.  Gallbladder cancer.

Authors:  Mislav Rakić; Leonardo Patrlj; Mario Kopljar; Robert Kliček; Marijan Kolovrat; Bozo Loncar; Zeljko Busic
Journal:  Hepatobiliary Surg Nutr       Date:  2014-10       Impact factor: 7.293

2.  Long non-coding RNA FOXD2-AS1 functions as a tumor promoter in colorectal cancer by regulating EMT and Notch signaling pathway.

Authors:  X Yang; B Duan; X Zhou
Journal:  Eur Rev Med Pharmacol Sci       Date:  2017-08       Impact factor: 3.507

3.  CPT-11 (SN-38) chemotherapy may be selectively applicable to biliary tract cancer with low hMLH1 expression.

Authors:  Ken Sato; Yoshihiko Kitajima; Naohiko Kohya; Yasuo Koga; Kazuma Ohtaka; Kohji Miyazaki
Journal:  Anticancer Res       Date:  2007 Mar-Apr       Impact factor: 2.480

4.  [Analysis of in vitro anti-leukemia effect of 5-aza-2'-deoxycitydine].

Authors:  Yan-hua Xiao; Hong Yi; Tan Tan; Ting Liang; Zhu-chu Chen; Zhi-qiang Xiao
Journal:  Zhong Nan Da Xue Xue Bao Yi Xue Ban       Date:  2008-04

Review 5.  Gallbladder cancer: epidemiology and outcome.

Authors:  Rajveer Hundal; Eldon A Shaffer
Journal:  Clin Epidemiol       Date:  2014-03-07       Impact factor: 4.790

  5 in total
  3 in total

1.  Hepatic microRNA modulation might be an early event to non-alcoholic fatty liver disease development driven by high-fat diet in male mice.

Authors:  Carolina Panzarin; Laís Angélica de Paula Simino; Mariana Camargo Silva Mancini; Leticia Martins Ignácio-Souza; Marciane Milanski; Márcio Alberto Torsoni; Adriana Souza Torsoni
Journal:  Mol Biol Rep       Date:  2022-01-20       Impact factor: 2.316

Review 2.  The role of FOXD2-AS1 in cancer: a comprehensive study based on data mining and published articles.

Authors:  Yongping Zhang; Chaojie Liang; Yu Zhang; Zhinmin Wang; Ruihuan Li; Zhigang Wei; Jiansheng Guo
Journal:  Biosci Rep       Date:  2020-11-27       Impact factor: 3.840

3.  Identification and in vitro validation of prognostic lncRNA signature in head and neck squamous cell carcinoma.

Authors:  Jian Wang; Qinjiang Bian; Jialin Liu; Adili Moming
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.